Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease

Physiology and Behavior

Volumn 104, Issue 1, 2011, Pages 168-172

  Ahlskog, J Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

Dopamine agonist; Dopamine D3; Impulse control disorders; Parkinson's disease

Indexed keywords

CARBIDOPA; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; BEHAVIOR; CARDIOTOXICITY; DRUG RECEPTOR BINDING; HUMAN; HYPERPHAGIA; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; SHOPPING;

ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOPAMINE AGONISTS; HUMANS; IMPULSE CONTROL DISORDERS; INDOLES; PARKINSON DISEASE;

EID: 79957666854     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2011.04.055     Document Type: Article

References (42)

1. Gerlach M., Double K., Arzberger T., Leblhuber F., Tatschner T., Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003, 110(10):1119-1127.
2. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature Sep. 13 1990, 347(6289):146-151.
3. Gurevich E.V., Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology Jan. 1999, 20(1):60-80.
4. Driver-Dunckley E., Samanta J., Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology Aug. 12 2003, 61(3):422-423.
5. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol Sep. 2005, 62(9):1377-1381.
6. Gallagher D.A., O'Sullivan S.S., Evans A.H., Lees A.J., Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord Sep. 15 2007, 22(12):1757-1763.
7. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord Sep. 2005, 11(6):381-386.
8. Nirenberg M.J., Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord Apr. 2006, 21(4):524-529.
9. McKeon A., Josephs K.A., Klos K.J., Hecksel K., Bower J.H., Bostwick J.M., et al. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord Dec. 2007, 13(8):516-519.
10. Hassan A., Bower J.H., Kumar N., Matsumoto J.Y., Fealey R.D., Josephs K.A., Ahlskog J.E. Dopamine agonist-triggered pathological behaviors: Surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011 May, 17(4):260-264.
11. Voon V., Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol August 1 2007, 64(8):1089-1096. 10.1001/archneur.64.8.1089.
12. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol May 2010, 67(5):589-595.
13. Bostwick J.M., Hecksel K.A., Stevens S.R., Bower J.H., Ahlskog J.E. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc April 2009, 84(4):310-316.
14. Rascol O., Brooks D., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484-1491.
15. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003, 54:93-101.
16. Parkinson-Study-Group A randomized controlled trial comparing the agonist pramipexole with levodopa as initial dopaminergic treatment for Parkinson's disease. JAMA 2000, 284:1931-1938.
17. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004, 61(7):1044-1053.
18. O'Sullivan S.S., Djamshidian A., Ahmed Z., Evans A.H., Lawrence A.D., Holton J.L., et al. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Mov Disord 2010, 25(5):638-642.
19. Driver-Dunckley E.D., Noble B.N., Hentz J.G., Evidente V.G., Caviness J.N., Parish J., et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007, 30(5):249-255.
20. Tippmann-Peikert M., Park J.G., Boeve B.F., Shepard J.W., Silber M.H. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology Jan. 23 2007, 68(4):301-303.
21. Quickfall J., Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord Dec. 2007, 13(8):535-536.
22. Pourcher E., Remillard S., Cohen H. Compulsive habits in restless legs syndrome patients under dopaminergic treatment. J Neurol Sci Mar. 15 2010, 290(1-2):52-56.
23. Cornelius J.R., Tippmann-Peikert M., Slocumb N.L., Frerichs C.F., Silber M.H. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep Jan 1 2010, 33(1):81-87.
24. Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci November 1 2007, 19(4):473-474.
25. Falhammar H., Yarker J.Y. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust Jan. 19 2009, 190(2):97.
26. Singh A., Kandimala G., Dewey R.B., O'Suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci Dec. 2007, 14(12):1178-1181.
27. Voon V., Sohr M., Lang A.E., Potenza M.N., Siderowf A.D., Whetteckey J., et al. Impulse control disorders in parkinson disease: a multicenter case-control study. Ann Neurol Jan. 10 2011.
28. Voon V., Hassan K., Zurowski M., et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology Jun. 13 2006, 66(11):1750-1752.
29. Wingo T.S., Evatt M., Scott B., Freeman A., Stacy M. Impulse control disorders arising in 3 patients treated with rotigotine. Clin Neuropharmacol Mar-Apr. 2009, 32(2):59-62.
30. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. Jan;67(1):58-63.
31. Steeves T.D., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., Van Eimeren T., et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain May 2009, 132(Pt 5):1376-1385.
32. O'Sullivan S.S., Wu K., Politis M., Lawrence A.D., Evans A.H., Bose S.K., et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain Apr. 2011, 134(Pt 4):969-978.
33. Frosini D., Pesaresi I., Cosottini M., Belmonte G., Rossi C., Dell'Osso L., et al. Parkinson's disease and pathological gambling: results from a functional MRI study. Mov Disord Oct. 30 2010, 25(14):2449-2453.
34. Ye Z., Hammer A., Camara E., Munte T.F. Pramipexole modulates the neural network of reward anticipation. Hum Brain Mapp May 2010, 32(5):800-811.
35. Voon V., Thomsen T., Miyasaki J.M., de Souza M., Shafro A., Fox S.H., et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol Feb. 2007, 64(2):212-216.
36. Djamshidian A., Jha A., O'Sullivan S.S., et al. Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Mov Disord. Oct 15 2010, 25(13):2203-2210.
37. Voon V., Pessiglione M., Brezing C., Gallea C., Fernandez H.H., Dolan R.J., et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron Jan. 14 2010, 65(1):135-142.
38. Higley A.E., Spiller K., Grundt P., Newman A.H., Kiefer S.W., Xi Z.X., et al. PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol Feb. 2011, 25(2):263-273.
39. Khaled M.A., Farid Araki K., Li B., Coen K.M., Marinelli P.W., Varga J., et al. The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacol Mar. 2010, 13(2):181-190.
40. Peng X.Q., Ashby C.R., Spiller K., Li X., Li J., Thomasson N., et al. The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology Mar. 2009, 56(4):752-760.
41. Graff-Guerrero A., Redden L., Abi-Saab W., Katz D.A., Houle S., Barsoum P., et al. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol Apr. 2010, 13(3):273-287.
42. Searle G., Beaver J.D., Comley R.A., Bani M., Tziortzi A., Slifstein M., et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry Aug. 15 2010, 68(4):392-399.